Having trouble accessing articles? Reset your cache.

Genzyme, Isis report mipomersen data

Genzyme Corp. (NASDAQ:GENZ) and partner Isis Pharmaceuticals Inc. (NASDAQ:ISIS) said two Phase III trials of mipomersen to treat hypercholesterolemia met their

Read the full 210 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE